Takeda’s Mezagitamab ITP Extension Study: Long-Term Data That Matters for Investors

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study.

Study Overview: Takeda is running a Phase 3 continuation trial called “A Phase 3, Open-label, Multicenter Continuation Trial to Evaluate the Long-term Safety and Efficacy of Mezagitamab Subcutaneous Injection in Adults With Chronic Primary Immune Thrombocytopenia.” The study tracks long-term safety and benefit of mezagitamab in adults with chronic immune thrombocytopenia, a bleeding disorder caused by low platelets. Its main goal is to see how well patients tolerate ongoing treatment and how stable their condition stays over time, which matters for long-term use and potential label strength if the drug reaches market.

Intervention/Treatment: The trial tests mezagitamab, also known as TAK-079, given as a subcutaneous injection. It is designed to help raise and stabilize platelet counts in people whose immune systems are destroying their platelets. In this continuation study, eligible patients from earlier mezagitamab trials receive on-demand dosing when specific clinical criteria are met.

Study Design: This is an interventional Phase 3 study with a single treatment group, so all enrolled participants receive mezagitamab. There is no randomization or placebo control, and the study is open-label, meaning both doctors and patients know what is being given. The main purpose is treatment, with a focus on long-term safety and durability of response rather than direct comparison with another therapy.

Study Timeline: The study was first submitted on April 25, 2025, marking the start of regulatory tracking and site activation. The trial is currently listed as recruiting, and no primary or final completion dates are yet posted, which suggests follow-up is expected to extend over several years to gather enough long-term safety data. The most recent update was filed on February 3, 2026, indicating the protocol and status information are current and that the program remains active.

Market Implications: For investors, this continuation study supports Takeda’s push to build a durable franchise in immune thrombocytopenia, a market that already includes steroids, thrombopoietin receptor agonists, and newer biologic agents. Long-term safety and sustained response data are often critical for biologics used in chronic conditions, and a positive readout could strengthen the commercial case for mezagitamab, support pricing power, and extend treatment duration per patient. While near-term earnings impact is limited, steady progress and timely updates can lift sentiment around Takeda’s hematology pipeline and may be viewed as a modest positive versus competitors developing next-generation ITP therapies. The study is ongoing and updated, with further details available on the ClinicalTrials.gov portal under identifier NCT06948318.

To learn more about TAK’s potential, visit the Takeda Pharmaceutical Company drug pipeline page.